Bendamustine salvage therapy for T cell neoplasms

Francesco Zaja, Luca Baldini, Andrés J M Ferreri, Stefano Luminari, Alberto Grossi, Flavia Salvi, Renato Zambello, Maria Goldaniga, Stefano Volpetti, Renato Fanin

Research output: Contribution to journalArticlepeer-review


Treatment of relapsed/refractory T cell neoplasms represents an unmet medical need. We recorded, retrospectively, data on 20 consecutive adult patients with T cell neoplasms (8 T cell lymphoma not otherwise specified (T-NOS), 4 angioimmunoblastic (AILT), 3 prolymphocytic leukemia (T-PLL), 3 advance-stage mycosis fungoides (MF) or Sézary syndrome (SS), and 2 T cell large granular lymphocytic leukemia (T-LGL)), treated with bendamustine. Partial (PR) and complete response (CR) rates were reached in nine (45 %) and two (10 %) patients, respectively, including three PR in T-NOS, one CR in AILT, three PR in T-PLL, two PR in MF/SS, and one CR and one PR in T-LGL lymphoma. The 6 months estimated progression free and overall survival was 44 and 67 %, respectively. Grade 3-4 neutropenia and thrombocytopenia were registered in 44 and 25 % of cases. Four patients developed major infectious complications. At a median follow-up of 6 months (range 1-18), 13 patients are alive and 7 patients died all because of lymphoma progression. Bendamustine deserves further investigation in patients with T cell neoplasms.

Original languageEnglish
Pages (from-to)1249-1254
Number of pages6
JournalAnnals of Hematology
Issue number9
Publication statusPublished - Sep 2013


  • Bendamustine
  • Chemotherapy
  • T cell lymphoma

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Bendamustine salvage therapy for T cell neoplasms'. Together they form a unique fingerprint.

Cite this